{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:25:40Z","timestamp":1783074340082,"version":"3.54.6"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3988,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1093\/annonc\/mdn526","type":"journal-article","created":{"date-parts":[[2008,7,23]],"date-time":"2008-07-23T00:59:30Z","timestamp":1216774770000},"page":"137-145","source":"Crossref","is-referenced-by-count":324,"title":["Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan"],"prefix":"10.1016","volume":"20","author":[{"given":"C.I.","family":"Ripamonti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maniezzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Campa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fagnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brunelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Saibene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bareggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ascani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cislaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn526_bb0010","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mdn526_bb0015","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn526_bb0020","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdn526_bb0025","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdn526_bb0030","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdn526_bb0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"key":"10.1093\/annonc\/mdn526_bb0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1034\/j.1600-0609.2002.02796.x","article-title":"Bisphosphonate therapy in multiple myeloma: past, present, future","volume":"69","author":"Jantunen","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdn526_bb0045","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn526_bb0050","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn526_bb0055","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn526_bb0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of multiple myeloma. MRC Working party on leukaemia in effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdn526_bb0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn526_bb0070","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00520-007-0230-2","article-title":"Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study","volume":"15","author":"Ripamonti","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdn526_bb0075","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of ZOL compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn526_bb0080","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumours: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumours Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn526_bb0085","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of ZOL for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdn526_bb0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdn526_bb0095","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn526_bb0100","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","article-title":"American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer","volume":"18","author":"Hillner","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn526_bb0105","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdn526_bb0110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumors: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdn526_bb0115","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","article-title":"International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients","volume":"43","author":"Body","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdn526_bb0120","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn526_bb0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdn526_bb0130","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1093\/annonc\/mdn526_bb0135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdn526_bb0140","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdn526_bb0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","article-title":"Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer","volume":"2","author":"Ruggiero","year":"2006","journal-title":"J Oncol Pharm Pract"},{"key":"10.1093\/annonc\/mdn526_bb0150","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdn526_bb0155","first-page":"21","article-title":"Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws","volume":"64","year":"2004","journal-title":"LDA J"},{"key":"10.1093\/annonc\/mdn526_bb0160","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis. An American Academy of Oral Medicine position paper","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.1093\/annonc\/mdn526_bb0165","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.bdj.4812376","article-title":"Special precautions","volume":"198","author":"Nelson","year":"2005","journal-title":"Br Dent J"},{"key":"10.1093\/annonc\/mdn526_bb0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1191\/026921601678320287","article-title":"The role of disodium pamidronate in the management of bone pain due to malignancy","volume":"15","author":"Groff","year":"2001","journal-title":"Palliat Med"},{"key":"10.1093\/annonc\/mdn526_bb0175","first-page":"99","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"3531","author":"Durie","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341939948X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341939948X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/1\/137\/19445728\/mdn526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:33:59Z","timestamp":1624437239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341939948X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S092375341939948X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn526","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}